Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Feb 11  •  12:03PM ET
16.94
Dollar change
-0.21
Percentage change
-1.25
%
Index- P/E- EPS (ttm)-0.86 Insider Own89.25% Shs Outstand354.09M Perf Week2.33%
Market Cap6.00B Forward P/E21.03 EPS next Y0.81 Insider Trans0.00% Shs Float38.07M Perf Month-3.22%
Enterprise Value10.69B PEG1.05 EPS next Q0.36 Inst Own10.21% Short Float8.83% Perf Quarter6.05%
Income-305.00M P/S1.21 EPS this Y-15.62% Inst Trans0.14% Short Ratio9.07 Perf Half Y22.99%
Sales4.98B P/B0.93 EPS next Y51.47% ROA-2.23% Short Interest3.36M Perf YTD-0.84%
Book/sh18.16 P/C18.07 EPS next 5Y20.07% ROE-4.69% 52W High17.86 -5.17% Perf Year5.20%
Cash/sh0.94 P/FCF- EPS past 3/5Y- - ROIC-2.69% 52W Low10.45 62.07% Perf 3Y1.97%
Dividend Est.- EV/EBITDA18.75 Sales past 3/5Y8.36% 4.87% Gross Margin54.02% Volatility3.10% 2.63% Perf 5Y-
Dividend TTM- EV/Sales2.15 EPS Y/Y TTM17.53% Oper. Margin2.85% ATR (14)0.45 Perf 10Y-
Dividend Ex-Date- Quick Ratio0.98 Sales Y/Y TTM6.23% Profit Margin-6.13% RSI (14)51.10 Recom2.44
Dividend Gr. 3/5Y- - Current Ratio1.51 EPS Q/Q-799.12% SMA200.10% Beta0.60 Target Price17.54
Payout- Debt/Eq0.77 Sales Q/Q7.11% SMA50-0.17% Rel Volume0.33 Prev Close17.15
Employees13500 LT Debt/Eq0.77 EarningsFeb 18 BMO SMA20015.44% Avg Volume370.83K Price16.94
IPOMay 06, 2022 Option/ShortYes / Yes EPS/Sales Surpr.12.85% 0.27% Trades Volume51,947 Change-1.25%
Date Action Analyst Rating Change Price Target Change
Jan-05-26Downgrade Evercore ISI Outperform → In-line $18
Dec-11-25Upgrade Citigroup Neutral → Buy $20
Dec-02-25Upgrade Morgan Stanley Equal-Weight → Overweight $21
Oct-01-25Initiated Goldman Neutral $16
May-02-25Reiterated H.C. Wainwright Buy $20 → $15
Mar-28-25Downgrade Wells Fargo Overweight → Equal Weight $24 → $15
Dec-11-24Downgrade Citigroup Buy → Neutral $24 → $22
Dec-02-24Downgrade Morgan Stanley Overweight → Equal-Weight $19
Oct-15-24Upgrade Evercore ISI In-line → Outperform $19 → $25
Jul-10-24Initiated Raymond James Outperform $19
Feb-09-26 11:02PM
11:40AM
Jan-29-26 11:34PM
Jan-23-26 11:40AM
Jan-20-26 07:15AM
07:00AM Loading…
Jan-05-26 07:00AM
Jan-02-26 04:30PM
Dec-23-25 07:30AM
Dec-17-25 04:30PM
Dec-12-25 04:48PM
Dec-11-25 11:41AM
Dec-04-25 10:09PM
Dec-02-25 11:10AM
Nov-18-25 04:30PM
Nov-13-25 02:57PM
08:55AM Loading…
08:55AM
08:41AM
Nov-10-25 06:59AM
04:28AM
Nov-05-25 12:35AM
Nov-03-25 04:30PM
Oct-30-25 01:34AM
Oct-29-25 03:47PM
09:30AM
08:05AM
07:23AM
07:06AM
06:58AM
Oct-28-25 09:26AM
Oct-27-25 11:12PM
06:44PM Loading…
Oct-20-25 06:44PM
11:36AM
09:34AM
07:41AM
07:25AM
Oct-19-25 08:00PM
Oct-17-25 12:24PM
Oct-10-25 06:44PM
Oct-02-25 11:40AM
Oct-01-25 11:01AM
Sep-25-25 01:06PM
Sep-11-25 07:00AM
Sep-09-25 07:00AM
Sep-08-25 06:56PM
04:30PM
07:00AM
Sep-05-25 12:41AM
Aug-22-25 02:25PM
Aug-20-25 11:31PM
Aug-18-25 05:48PM
05:01PM
Aug-14-25 07:15AM
Aug-12-25 11:55PM
11:48PM
Aug-07-25 12:38AM
Jul-30-25 03:05PM
12:16PM
09:30AM
08:10AM
07:34AM
07:04AM
06:57AM
05:38AM
Jul-29-25 09:27AM
07:00AM
Jul-28-25 11:09PM
Jul-24-25 05:04AM
Jul-23-25 10:00AM
Jul-22-25 08:45AM
Jul-21-25 09:13AM
Jul-20-25 11:31PM
Jul-01-25 07:00AM
Jun-30-25 06:58AM
Jun-26-25 04:30PM
Jun-25-25 07:42AM
Jun-23-25 11:58AM
Jun-18-25 04:30PM
Jun-10-25 08:48AM
Jun-04-25 06:59AM
May-27-25 12:47PM
May-22-25 07:30AM
12:00AM
May-21-25 04:30PM
09:36AM
06:59AM
May-14-25 06:59AM
May-08-25 12:37AM
May-07-25 09:30AM
07:00AM
May-01-25 03:08AM
Apr-30-25 04:40PM
11:02AM
09:30AM
08:10AM
06:57AM
Apr-29-25 03:10AM
Apr-24-25 10:01AM
07:00AM
Apr-23-25 07:23PM
11:40AM
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SAUNDERS BRENT LCEO and Chairman of the BoardMay 22 '25Buy11.2822,000248,072719,156May 27 08:16 AM
VON ESCHENBACH ANDREW C.DirectorMay 02 '25Buy11.761,69519,92541,748May 06 04:30 PM
BHC Bausch Health Companies Inc daily Stock Chart
Index- P/E6.29 EPS (ttm)0.97 Insider Own11.38% Shs Outstand370.47M Perf Week7.69%
Market Cap2.26B Forward P/E1.46 EPS next Y4.17 Insider Trans- Shs Float328.35M Perf Month-18.62%
Enterprise Value22.88B PEG- EPS next Q1.20 Inst Own67.71% Short Float1.65% Perf Quarter-4.77%
Income362.00M P/S0.23 EPS this Y-4.24% Inst Trans-16.58% Short Ratio2.20 Perf Half Y-12.93%
Sales10.03B P/B- EPS next Y8.47% ROA1.36% Short Interest5.41M Perf YTD-12.30%
Book/sh-1.53 P/C1.69 EPS next 5Y-1.80% ROE- 52W High8.69 -29.82% Perf Year-4.32%
Cash/sh3.62 P/FCF2.16 EPS past 3/5Y63.83% 52.33% ROIC1.82% 52W Low4.25 43.41% Perf 3Y-14.87%
Dividend Est.- EV/EBITDA6.97 Sales past 3/5Y4.50% 2.28% Gross Margin60.45% Volatility3.34% 3.77% Perf 5Y-79.76%
Dividend TTM- EV/Sales2.28 EPS Y/Y TTM301.53% Oper. Margin20.50% ATR (14)0.25 Perf 10Y-92.70%
Dividend Ex-DateNov 10, 2010 Quick Ratio0.97 Sales Y/Y TTM5.86% Profit Margin3.61% RSI (14)44.36 Recom3.25
Dividend Gr. 3/5Y- - Current Ratio1.30 EPS Q/Q306.63% SMA20-0.96% Beta0.37 Target Price7.43
Payout- Debt/Eq- Sales Q/Q6.81% SMA50-9.62% Rel Volume0.40 Prev Close6.16
Employees20700 LT Debt/Eq- EarningsFeb 18 AMC SMA200-3.93% Avg Volume2.46M Price6.09
IPOMar 29, 1994 Option/ShortYes / Yes EPS/Sales Surpr.9.49% 2.09% Trades Volume420,127 Change-1.06%
Date Action Analyst Rating Change Price Target Change
Dec-09-25Initiated Barclays Equal Weight $8
Aug-02-24Downgrade Piper Sandler Neutral → Underweight $9 → $3
Jul-10-24Initiated Raymond James Mkt Perform $8
Sep-20-23Upgrade Jefferies Hold → Buy $9 → $16
Jun-16-23Downgrade TD Cowen Outperform → Market Perform
Jul-29-22Downgrade Truist Buy → Hold
Jul-29-22Downgrade RBC Capital Mkts Outperform → Sector Perform $12 → $5
Jul-28-22Downgrade JP Morgan Overweight → Neutral
Jun-13-22Resumed JP Morgan Overweight $12
Mar-24-21Downgrade BofA Securities Neutral → Underperform $27
Today 10:00AM
08:00AM
Feb-09-26 03:26AM
Feb-06-26 02:02PM
11:28AM
10:34AM Loading…
10:34AM
Feb-03-26 11:20PM
11:23AM
Jan-31-26 08:15AM
Jan-27-26 02:07PM
Jan-26-26 10:35AM
09:35AM
Jan-23-26 07:45AM
Jan-21-26 07:00AM
Jan-05-26 07:00AM
01:34PM Loading…
Dec-29-25 01:34PM
Dec-23-25 05:35PM
Dec-08-25 07:22PM
Dec-02-25 02:20PM
Dec-01-25 07:02PM
04:34PM
12:41PM
07:00AM
Nov-28-25 11:30AM
Nov-25-25 08:42AM
Nov-24-25 07:05AM
Nov-19-25 12:00PM
Nov-18-25 07:00AM
Nov-14-25 05:05PM
Nov-13-25 11:37PM
02:57PM Loading…
02:57PM
Nov-10-25 12:20PM
Nov-05-25 08:00AM
Oct-30-25 04:08PM
10:28AM
05:07AM
Oct-29-25 04:05PM
03:47PM
Oct-22-25 10:00AM
Oct-20-25 06:44PM
Oct-10-25 06:44PM
Oct-09-25 07:00AM
Sep-30-25 08:00AM
07:00AM
Sep-29-25 08:00AM
Sep-21-25 05:30AM
Sep-19-25 01:45PM
Sep-16-25 09:32AM
Sep-11-25 08:35AM
Sep-08-25 06:56PM
Sep-05-25 08:02AM
Aug-29-25 11:30AM
05:06AM
Aug-26-25 08:00AM
Aug-21-25 08:02AM
Aug-18-25 05:48PM
12:50PM
Aug-15-25 02:30PM
Aug-12-25 04:30PM
10:37AM
05:37AM
Aug-08-25 11:52PM
Aug-07-25 08:31AM
08:00AM
Aug-05-25 08:51AM
Jul-31-25 10:48AM
05:27AM
03:36AM
Jul-30-25 09:00PM
08:25PM
07:16PM
04:05PM
03:05PM
Jul-29-25 07:00AM
Jul-28-25 04:06PM
09:10AM
Jul-24-25 08:02AM
Jul-11-25 11:27AM
04:07AM
Jul-10-25 05:00PM
04:15PM
Jul-09-25 08:00AM
Jul-07-25 08:00AM
Jul-02-25 07:00AM
Jun-27-25 07:03PM
Jun-22-25 05:00AM
Jun-14-25 09:07AM
May-30-25 11:31AM
May-14-25 04:15PM
May-13-25 06:28AM
May-09-25 05:00AM
May-08-25 05:29AM
May-07-25 08:45AM
May-06-25 08:00AM
May-01-25 09:48AM
03:18AM
Apr-30-25 08:30PM
08:05PM
07:51PM
07:00PM
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PAULSON & CO. INC.10% OwnerNov 25 '25Buy6.252,500,00015,625,00073,255,869Nov 28 05:38 PM
Carson SeanaEVP, General CounselSep 08 '25Sale7.3113,37097,735499,585Sep 08 04:37 PM
Carson SeanaOfficerSep 08 '25Proposed Sale7.3113,37097,735Sep 08 10:16 AM
Lee Frank D.DirectorAug 21 '25Sale7.6615,912121,88673,795Aug 22 04:19 PM
Lee Frank D.DirectorAug 21 '25Proposed Sale7.6615,912121,888Aug 21 12:24 PM
Paulson JohnDirectorAug 14 '25Buy9.0034,721,118312,490,06270,755,869Aug 14 09:35 PM
Paulson JohnDirectorAug 11 '25Buy6.352,000,00012,700,00034,791,702Aug 13 06:51 PM
Paulson JohnDirectorAug 12 '25Buy6.881,156,6407,957,68335,948,342Aug 13 06:51 PM
Paulson JohnDirectorAug 13 '25Buy7.0686,409610,04836,034,751Aug 13 06:51 PM
Paulson JohnDirectorJun 13 '25Buy5.943,564,05921,170,51032,791,702Jun 17 04:44 PM
Paulson JohnDirectorJun 12 '25Buy5.471,005,3765,499,40729,227,643Jun 12 08:17 PM
Paulson JohnDirectorJun 11 '25Buy5.241,029,0985,392,47428,222,267Jun 12 08:17 PM
Paulson JohnDirectorJun 10 '25Buy5.05754,1343,808,37727,193,169Jun 12 08:17 PM